Background: The most common cystic fibrosis-associated mutation, the deletion of phenylalanine 508 (F508del), results in channels with poor membrane expression and impaired function. VX-770, a clinically approved drug for treatment of CF patients carrying the G551D mutation, and VX-809, a corrector shown in vitro to increase membrane expression of mutant channels, are currently undergoing clinical trials, but functional data at the molecular level is still lacking. 
Introduction
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a chloride channel that plays a critical role in maintaining fluid and electrolyte balance across many epithelium-lining tissues [1] . Mutations in CFTR that decrease the channel expression and function result in the lethal hereditary disease cystic fibrosis (CF) [1, 2] .
The CFTR channel is composed of two transmembrane domains (TMDs), two nucleotide-binding domains (NBDs), and a regulatory domain (RD). Phosphorylation of the RD by PKA (protein kinase A) is required for the channel to function. ATP binding to the NBDs leads to the formation of an NBD dimer with the ATP trapped at the dimer interface triggering channel opening. Hydrolysis of the ATP bound at the NBD2 site leads to the partial separation of the dimer and channel closure (for a comprehensive review see Ref. [3] ). This partial NBD dimer, lasting for tens of seconds, allows another ATP molecule to bind to NBD2 and initiate a new gating cycle. CFTR channels can open also in the absence of ATP, although very infrequently [4] .
Deletion of phenylalanine 508 (F508del) is the most common CF-associated mutation [5] . F508del-CFTR channels exhibit defective protein production and processing [6, 7] , defective function [7] [8] [9] [10] and reduced cell membrane lifetime [11, 12] . Recently we demonstrated several functional defects for F508del channels [10, 13] : the open probability (Po) of F508del-CFTR is~15 times lower than that of wild-type (WT) channels [10] , which can be completely rectified by the ATP-analog P-dATP [10] ; F508del-CFTR channels also have shortened lockedopen time, and ligand-exchange time at the NBD1 site (non-hydrolytic) suggesting that the mutation may destabilize the full and partial NBD dimer states [13] .
ATP analogs are unsuitable for therapeutic use, but smallmolecules can be used for targeted treatment in CF. VX-770 (Ivacaftor) is the first CFTR potentiator approved by the Food and Drug Administration (USA), the European Medicines Agency, Health Canada and the Therapeutic Goods Administration in Australia, for clinical application to patients 6-years and older carrying the G551D mutation which targets the molecular defect of the protein [14, 15] . Bompadre et al. [4] demonstrated that the G551D mutation abolishes the ATP-dependent gating of these channels, exhibiting only ATP-independent openings. Not surprisingly, VX-770 potentiates G551D-CFTR activity by increasing the ATP-independent opening-rate and the open time [16, 17] . VX-770 also increases the ATP-dependent activity of WT-CFTR channels [17] , as well as other CFTR mutants only when present at the cell surface, including F508del [14, 18, 19] .
F508del-CFTR channels have primarily a folding and processing defect and considerable effort is centered in finding compounds (correctors) to improve the trafficking problem. Recently a new compound, VX-809, emerged as a plausible corrector specifically addressing the underlying processing defect in F508del-CFTR, allowing quantifiable amounts of CFTR to traffic to the cell surface [20] . A study of VX-809 on patients homozygous for the F508del mutation did not show improvements in clinical outcomes [21] suggesting that even if VX-809 corrected channel trafficking, their function may still be defective. A new clinical study combining both VX-770 and VX-809 is currently underway (ClinicalTrials.gov identifier NCT0122521). Interestingly, detailed functional data at the molecular level demonstrating the effect of this drug combination is still lacking.
In this study we tested the effect of VX-770 on the different functional defects associated with F508del channels. We found that VX-770 increases the activity of the mutant channels expressed in Chinese hamster ovary (CHO) cells as well as human epithelial CFPAC-1 cells mainly by increasing the ATPdependent opening-rate of the channels, similar to the effect produced by P-dATP [10] . VX-770 also reduces the hydrolytic and non-hydrolytic closing-rates. Contrary to what has been reported [20] , F508del channels treated with corrector VX-809 did not show improved function, having similar activity to that of low temperature-corrected channels. On the other hand, channels treated with VX-809 and VX-770 resulted in increased channel expression at the membrane and maximally potentiated activity, indicating that the combination of both compounds could be a viable treatment for people bearing the F508del mutation, provided the level of correction induced by VX-809 is sufficient.
Results

Effect of VX-770 on the low opening-rate of F508del-CFTR
We studied the effect of the potentiator VX-770 in F508del-CFTR channels expressed in CHO and human CFPAC-1 cells via patch-clamp experiments in the inside-out mode. We compared it to the effect of the high-affinity ATP-analog P-dATP, which we showed to maximally potentiate F508del-CFTR currents since the addition of genistein, a well-known CFTR potentiator [22] , failed to further increase the current induced by P-dATP [10] . The cells were incubated at 27°C for 48 h to allow for the correction of the trafficking defect of these channels.
After the channels were activated with 2 mM ATP + 20 U/ml PKA, the addition of 200 nM VX-770, a saturating concentration [17] , resulted in a 13 ± 3 fold increase of the steady-state ATP-elicited current (n = 8). To determine whether the increase in the current was due to an increase in the open time or the opening-rate of the channels, we used patches containing no more than 4 channels to perform single-channel kinetic analysis. . The observed potentiation effect by VX-770 was very similar to the one reported for the high-affinity ATP analog P-dATP [10] . The channels were also exposed to 10 μM P-dATP, in conjunction with VX-770 (Fig. 1A) , in order to determine if it could further potentiate the channel activity. P-dATP further increased the ATP + VX-770 induced current by 35 ± 5% (n = 8), indicating that 200 nM VX-770 almost completely rectified the low Po of temperature-corrected F508del-CFTR channels.
Experiments carried out with human CFPAC-1 cells expressing recombinant F508del-CFTR show that 200 nM VX-770 increased the Po of F508del-CFTR to 0.38 ± 0.10 (n = 5), a value comparable to that of F508del-CFTR channels expressed in CHO cells.
Effect of VX-770 on F508del-CFTR channels corrected with VX-809
The corrector VX-809 has been shown in vitro to increase the amount of CFTR proteins present at the cell membrane by 34% [20, 23] , as well as to improve the Po of the channels [20] .
First we examined the level of potentiation induced by VX-809 on F508del-CFTR channels expressed in CHO cells and CFPAC-1 cells. Fig. 2A -B shows that 10 μM P-dATP increased the current by 15.4 ± 1.5 fold, compared to 2 mM ATP, in CHO cells (n = 6) and 9.6 ± 1.7 fold in CFPAC-1 cells (n = 5), indicating that the Po of VX-809-treated F508del channels is still very low. The low Po found for VX-809-treated F508del-CFTR (Po = 0.036 ± 0.006, n = 14) does not agree with previous findings (Po = 0.39 ± 0.04, [20] ). The reason for the discrepancy could be due to different experimental conditions or the different cell lines. Interestingly, the clinical trial of this compound did not show improvement in CFTR function [21] .
Next, we tested the effect of VX-770 on F508del channels treated with VX-809 and found similar results to those of temperature-corrected channels (Fig. 2C-D) . Table 1 summarizes the kinetic parameters for F508del-CFTR channels expressed in CHO and CFPAC-1 cells treated with 3 μM VX-809 in the presence and absence of 200 nM VX-770 (n = 6-16). The viability of this drug combination as a therapeutic option will ultimately depend on the effectiveness of correction induced by VX-809.
Effect of VX-770 on the locked-open state of F508del-CFTR
We have previously shown that the F508del mutation decreases the locked-open time of hydrolysis-deficient channels [13] , suggesting perhaps a destabilization of the NBD dimer conformation.
Here we gauge the effect of VX-770 on this functional defect of F508del-CFTR. We introduced the E1371S mutation, which abolishes ATPase activity [24] , in WT and F508del-CFTR channels and expressed them in CHO cells. The duration of the locked-open time of the channels is calculated from the timeconstants of F508del/E1371S and E1371S-CFTR current relaxations upon ATP withdrawal. As shown in Fig. 3A-B, 200 nM VX-770 prolonged the locked-open times of hydrolysis-deficient channels with and without the F508del mutation. The relaxation time constant increases about 60% for both F508del/E1371S and E1371S-CFTR, suggesting that the effect may not be specific to the mutant channel.
The high-affinity ATP analog P-ATP has been shown to stabilize the open time of WT-CFTR [25] and F508del-CFTR similar to that of E1371S-CFTR channels in the absence of VX-770, indicating that VX-770 alone is not sufficient to fully restore the stability of the open-channel conformation of F508del channels when hydrolysis is abolished.
Effect of VX-770 on the resident time of ATP at NBD1
Another functional defect of F508del-CFTR channels we recently unveiled is the shorter resident-time of ATP bound at NBD1 [13] . For WT channels ATP remains bound at this site for tens of seconds [26] . On the other hand for F508del-CFTR channels this time is reduced to 3 s [13] , suggesting a destabilization of the partial dimer configuration.
We performed a ligand-exchange protocol (ATP/P-ATP) in the presence of VX-770 to determine whether the lifetime of the partial dimer state in F508del is restored. In the absence of VX-770, when the ligand is switched from ATP to P-ATP, there is a fast current raising-phase, which represents the ATP/P-ATP exchange in the NBD2 site, followed by a slow current risingphase representing the ATP/P-ATP exchange in the NBD1 site [13] . The tightness of ligand binding at the NBD1 site can be examined quantitatively by measuring the time constant of the slow phase upon ligand-exchange. When the protocol is performed in the presence of 200 nM VX-770 (Fig. 4A) , the ATP/P-ATP switch resulted in a small current increase (40 ± 10%; n = 8) that could be fitted by a single exponential function with time constant 2.5 ± 0.5 s (n = 8), with no evident fast rising-phase. This value is similar to the slow-phase time constant (ATP/P-ATP exchange in NBD1) for F508del-CFTR channels in the absence of VX-770 [13] .
Kinetic analysis indicates that the main effect of P-ATP is to further increase the open time (55 ± 10%) with a smaller increase in the opening-rate (24 ± 8%) (Fig. 4B) . Thus if the current increase in Fig. 4A is due mainly to the increase in the open time (P-ATP binding to NBD1 site [25] ), then the ATP/P-ATP exchange at the NBD1 site occurs as fast as in F508del channels not exposed to VX-770. The lack of a fast rising-phase (ATP/ P-ATP exchange at NBD2) in the ligand-exchange experiments may be due to the large increase in the opening-rate already caused by VX-770. The faster ligand-exchange at NBD1 (partial dimer configuration) does not seem to be affected by VX-770, although the small current increase elicited by P-ATP warrants caution when interpreting the data.
Discussion
In this study we examined, at the molecular level, the effects of the clinically-approved drug VX-770 (Ivacaftor) on several functional defects of F508del-CFTR channels either treated with corrector VX-809, a combination currently under clinical trial, or low temperature-corrected. In both cases VX-770 increases the Po of F508del channels to WT levels by two different mechanisms: increasing the ATP-dependent opening-rate and slowing the closing-rate of the channels. Contrary to what was Table 1 Kinetic parameters for VX-809 or low temperature corrected F508del-CFTR channels in the presence of 2 mM ATP and 2 mM ATP + 200 nM VX-770 for different cell lines. Channels were later exposed to 10 μM P-dATP to accurately determine the number of channels present in the patch (n = 5-23).
VX-809
Low The F508del mutation causes defective protein folding and assembly resulting in very poor expression at the cell membrane [6] . Partial correction of this trafficking defect is achieved in vitro by incubating the cells at 27°C [7] , or by small-molecule "correctors", like the recently discovered compound VX-809 [20] . In both cases, the channels that reach the cell membrane have defective function. The Po is extremely low, around 0.03, 15 times lower than that of WT channels, due to a greatly diminished opening-rate [10] . Here we show that this low Po can be corrected by VX-770, mainly by greatly increasing the opening-rate and increasing the open time of the channels. We also show that the effect of VX-770 on F508del-CFTR mimics the effect of P-dATP, which we have demonstrated to maximally potentiate the channel activity [10] .
We also studied the effect of VX-770 on the other functional defects associated with F508del-CFTR channels, namely the The mechanism of action of VX-770 is not fully understood. VX-770 has shown some efficacy in improving the lung-function of CF patients carrying the G551D mutation. In vitro, it potentiates the activity of G551D-CFTR channels, a mutant that does not respond to ATP, by approximately 10 fold [14] . VX-770 also potentiates WT-CFTR activity by increasing the open time and the opening-rate of the channels in an ATP-dependent manner, as well as the ATP-independent activity of the channels [17] . Several other CFTR mutants exhibiting gating defects are potentiated by VX-770 [18, 19] .
Our data show that the main effect of VX-770 on F508del-CFTR is to increase dramatically the ATP-dependent openingrate of the channels. Based on recently proposed kinetic models [27] , we can interpret the increase in the opening-rate as a destabilization of the closed-state with two bound ATP molecules, shifting the equilibrium toward the open-state. Further evidence that this open-state is favored is provided by the decreased hydrolytic and non-hydrolytic closing rates.
The open time of CFTR channels is controlled by hydrolysis and can be modulated by the "tightness" of nucleotide binding at NBD1 (demonstrated for ATP-analogs or mutations) [25, 28] . A new mechanism has been proposed in which a new ATP molecule can bind to NBD2 after being vacated through hydrolysis, before the channel closes [27] . Facilitating this open-to-open transition by stabilizing the open-state with just one ATP bound at NBD1 leads to a lengthening of the open time of the channels [17] . This mechanism could explain the 3-fold increase in the open time of ΔF508 channels, since neither hydrolysis nor tighter nucleotide binding to NBD1 is likely responsible for this effect.
Whether VX-770 shifts the equilibrium toward the open-state of the channel by affecting the NBD dimeric conformation or the open conformation of the pore is not known at this point. Certainly more studies are needed to fully characterize the mechanism of action of this important compound.
In summary, this study provides the first description, at the molecular level, of the combined effect of VX-770 and VX-809, a combination undergoing clinical trials, on F508del-CFTR function. We show that VX-770 is perhaps the most potent drug available for VX-809-corrected F508del-CFTR channels. Whether the amount of correction provided by VX-809 is enough to be clinically relevant for patients with CF is still an open question that will likely be answered by ongoing medical studies.
Methods
CHO and CFPAC-1 cells were grown at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium and Iscove's modified Dulbecco's medium respectively, supplemented with 10% fetal bovine serum. CHO cells were transfected using Polyfect (Qiagen) and CFPAC-1 cells were infected with adenoviruses expressing ΔF508-CFTR as previously reported [10, 13] . Although the CFPAC-1 cell line was established from a pancreatic adenocarcinoma derived from a patient with CF [29] , the cells do not respond to cAMP stimulation [30] .
F508del-expressing cells were incubated at 27°C for 48 h or were treated with 3 μM VX-809 added to the culture medium and incubated at 37°C for 24-48 h before patch-clamp experiments.
Membrane currents were recorded at room-temperature (22-24°C) with an EPC10 amplifier (HEKA) as previously reported [13] . The membrane potential was held at − 60 mV and the inward current was inverted for clear data presentation.
Igor-Pro (WaveMetrics) was used to calculate steady-state mean currents and current relaxation time constants. Current traces containing fewer than five channel-opening levels were selected for single-channel kinetic analysis as described previously [10] . All averaged data are presented as mean ± SEM; n represents the number of patches from different cells.
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